IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $48.27 Consensus Target Price from Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have been assigned a consensus recommendation of “Buy” from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports. Thirteen investment analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $48.27.

A number of equities analysts recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $52.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, May 8th. BTIG Research initiated coverage on IDEAYA Biosciences in a report on Friday, March 8th. They issued a “buy” rating and a $55.00 price target for the company. The Goldman Sachs Group reduced their price objective on IDEAYA Biosciences from $53.00 to $46.00 and set a “buy” rating for the company in a research note on Monday, May 13th. Stifel Nicolaus boosted their price objective on IDEAYA Biosciences from $55.00 to $63.00 and gave the company a “buy” rating in a research note on Tuesday, June 4th. Finally, Citigroup boosted their price objective on IDEAYA Biosciences from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, March 21st.

IDEAYA Biosciences Stock Down 3.4 %

Shares of IDYA opened at $34.88 on Monday. The stock has a 50 day moving average price of $39.21 and a 200 day moving average price of $40.63. The company has a market capitalization of $2.64 billion, a price-to-earnings ratio of -17.35 and a beta of 0.79. IDEAYA Biosciences has a 52-week low of $20.90 and a 52-week high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.09%. The firm’s quarterly revenue was down 100.0% compared to the same quarter last year. During the same period last year, the company earned ($0.49) earnings per share. On average, equities analysts anticipate that IDEAYA Biosciences will post -2.37 EPS for the current fiscal year.

Insider Transactions at IDEAYA Biosciences

In other IDEAYA Biosciences news, CEO Yujiro S. Hata sold 56,711 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $41.61, for a total value of $2,359,744.71. Following the completion of the transaction, the chief executive officer now owns 677,887 shares in the company, valued at $28,206,878.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other IDEAYA Biosciences news, CEO Yujiro S. Hata sold 34,433 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $41.81, for a total value of $1,439,643.73. Following the completion of the transaction, the chief executive officer now owns 677,887 shares in the company, valued at $28,342,455.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Yujiro S. Hata sold 56,711 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $41.61, for a total value of $2,359,744.71. Following the completion of the transaction, the chief executive officer now owns 677,887 shares of the company’s stock, valued at approximately $28,206,878.07. The disclosure for this sale can be found here. Insiders sold 119,644 shares of company stock worth $4,832,228 over the last 90 days. 3.50% of the stock is currently owned by insiders.

Institutional Trading of IDEAYA Biosciences

Several large investors have recently bought and sold shares of IDYA. Covestor Ltd grew its holdings in IDEAYA Biosciences by 9,225.0% in the first quarter. Covestor Ltd now owns 1,119 shares of the company’s stock valued at $49,000 after purchasing an additional 1,107 shares during the last quarter. Comerica Bank grew its holdings in IDEAYA Biosciences by 723.5% in the first quarter. Comerica Bank now owns 1,507 shares of the company’s stock valued at $66,000 after purchasing an additional 1,324 shares during the last quarter. JTC Employer Solutions Trustee Ltd acquired a new stake in IDEAYA Biosciences in the first quarter valued at $67,000. AJOVista LLC acquired a new stake in shares of IDEAYA Biosciences during the fourth quarter valued at $99,000. Finally, SG Americas Securities LLC acquired a new stake in shares of IDEAYA Biosciences during the first quarter valued at $101,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.